Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

7(100.0%)

7Total

Phase 1(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03549299Phase 1Unknown

Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD

Role: collaborator

NCT03529877Phase 1Completed

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

Role: collaborator

NCT03257098Phase 1Completed

Allogeneic ABCB5-positive Stem Cells for Treatment of CVU

Role: collaborator

NCT03267784Phase 1Completed

Allogeneic ABCB5-positive Stem Cells for Treatment of DFU "Malum Perforans"

Role: collaborator

NCT02742844Phase 1Terminated

Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From Ulcers

Role: collaborator

NCT03339973Phase 1Terminated

Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD

Role: collaborator

NCT01808638Phase 1Completed

Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)

Role: collaborator

All 7 trials loaded